# How does the FDA approve software as a medical device?

hcco.app · November 8, 2026

> The FDA classifies software as a medical device based on its intended medical purpose, requiring manufacturers to determine the appropriate regulatory...

## defining software medical device classification

The FDA classifies software as a medical device based on its intended medical purpose, requiring manufacturers to determine the appropriate regulatory pathway before marketing. This process involves submitting a premarket submission, such as a 510(k) or De Novo request, which demonstrates substantial equivalence to an existing device or establishes reasonable assurance of safety and effectiveness. The agency evaluates clinical evidence, software functionality, and cybersecurity protocols to ensure the tool does not pose undue risks to patients. Manufacturers must also adhere to quality system regulations and provide detailed documentation outlining the software’s algorithmic logic, data handling procedures, and intended use within healthcare workflows.

**Also worth reading:** [How does healthcare AI audit software ensure compliance and reduce costs in modern medical operations?](https://hcco.app/knowledge/how_does_healthcare_ai_audit_software_ensure_compliance_and_reduce_costs_in_modern_medical_operations.php) · [How to calculate ROI for HCC coding software?](https://hcco.app/knowledge/how_to_calculate_roi_for_hcc_coding_software.php) · [How to choose best care management software uk?](https://hcco.app/knowledge/how_to_choose_best_care_management_software_uk-2.php)

Once the submission is reviewed and accepted, the FDA grants authorization, allowing the software to be legally marketed in the United States. This approval signifies that the device meets statutory requirements for safety and efficacy, though it does not imply endorsement of all features. Continuous post-market surveillance remains mandatory, requiring manufacturers to monitor real-world performance and report adverse events. For B2B healthcare platforms focused on cost containment and care coordination, this regulatory framework ensures that digital tools supporting payer and provider operations maintain rigorous standards. The approval process balances innovation with patient protection, enabling advanced health AI tools to integrate seamlessly into clinical environments while upholding public health integrity through ongoing federal oversight and compliance enforcement.

## premarket submission pathway options

For a platform like hcco.app, the most likely unresolved pathway question comes down to choosing between 510(k) clearance and De Novo classification. The 510(k) route applies when a sponsor can identify a legally marketed predicate device and demonstrate substantial equivalence, which is faster and cheaper but narrows design freedom to what predicates already support. The De Novo route suits novel devices of low to moderate risk with no suitable predicate, establishing a new classification that future competitors can then use as their own predicate. Both routes converge on the same submission infrastructure: FDA's device software guidance expects documentation of the software description, development process, risk management file, verification and validation testing, and increasingly a cybersecurity section addressing premarket security architecture and postmarket patching commitments under the agency's medical device cybersecurity expectations.

FDA's own framing of its public health mandate matters here, because the agency has signaled it wants to right-size oversight for lower-risk software while concentrating scrutiny on tools that drive clinical decisions. Cybersecurity documentation has shifted from optional context to a core element of submission adequacy.

## cybersecurity documentation requirements

FDA does not issue a single “approval” for every piece of software. If a SaMD meets the device definition and requires premarket review, the sponsor chooses 510(k), De Novo, or PMA based on risk and predicate status; FDA then clears, grants, or approves the submission after evaluating safety and effectiveness, including software lifecycle and cybersecurity evidence. Lower-risk products may fall under enforcement discretion or exemption, so no FDA authorization occurs.

The unresolved point is what documentation settles the cybersecurity review. Treat it as part of the premarket package: cybersecurity risk management, threat model, software bill of materials, secure design and lifecycle controls, security testing, vulnerability and patch management, and coordinated vulnerability disclosure. For a payer/provider SaaS product, first confirm whether its intended function makes it device software; if yes, align the submission and postmarket monitoring to these expectations. FDA authorization is pathway-specific, not a blanket software seal, and cybersecurity evidence must remain current after clearance.

## artificial intelligence regulatory framework

The FDA's pathway for software as a medical device hinges on risk classification, and the most consequential unresolved piece is how adaptive algorithms fit into a system built for static devices. Under existing rules, software intended to diagnose, treat, or manage disease is regulated like any device, with clearance through 510(k) when a predicate exists, de novo classification for novel low-to-moderate risk products, or premarket approval for high-risk tools. The agency has also finalized predetermined change control plans, letting manufacturers pre-specify how a machine learning model may be updated after authorization without a fresh submission each time.

Settling one open question: the FDA does not currently require real-world performance monitoring as a condition of authorization for most AI-enabled devices, but it is moving toward it. Recent guidance and the agency's digital health activity signal that postmarket surveillance, including lifecycle data reporting, will become an expectation rather than a voluntary practice, closing the gap between initial clearance and ongoing clinical performance.

## post market surveillance obligations

FDA does not apply a single “approval” route to software as a medical device. Most moderate-risk SaMD reaches market through 510(k) clearance, novel low- and moderate-risk devices may use De Novo authorization, and only high-risk PMA devices receive formal approval. Post-market surveillance obligations follow the authorization pathway and risk class, but commonly include medical device reporting, recall and correction procedures, labeling updates, and cybersecurity vulnerability monitoring with validated patches and user notifications. Payer and provider operations teams evaluating vendors such as hcco.app should require evidence of these controls rather than treating “FDA cleared” as a one-time badge.

The key unresolved issue is change management. FDA expects manufacturers to assess software changes for safety and effectiveness; significant changes may need a new submission, while authorized predetermined change control plans can cover specified AI/ML updates. Post-market duties are continuous: monitor real-world performance, investigate complaints, report adverse events, and document whether updates stay within cleared or approved claims. Buyers should verify quality-system, cybersecurity, and change-control records against actual regulatory status.

## SaMD submission pathway comparison

| Submission Type | Primary Use Case | Key Regulatory Requirement |
| --- | --- | --- |
| De Novo Classification | Low-to-moderate risk | Demonstrating general controls and special controls |
| 510(k) Clearance | Substantial equivalence | Comparing against a legally marketed predicate device |
| PMA Approval | High-risk devices | Clinical trials and rigorous scientific evidence |

The FDA regulates Software as a Medical Device (SaMD) through distinct pathways based on risk classification. Low-risk tools may utilize the De Novo process, while moderate-risk software often requires 510(k) clearance by demonstrating substantial equivalence to existing devices. High-risk applications demand Premarket Approval (PMA), necessitating robust clinical data. This structured approach ensures patient safety while accommodating technological innovation in digital health solutions.

## Quick answers

### What distinguishes SaMD from general wellness apps?

SaMD must be intended for diagnosis, cure, mitigation, treatment, or prevention of disease.

### Which submission route applies to low risk devices?

The 510(k) pathway is typically used for moderate risk devices with substantial equivalence.

### How does FDA evaluate algorithm changes?

Manufacturers must submit premarket notifications for significant algorithmic modifications affecting safety.

### What are post market surveillance requirements?

Companies must monitor performance and report adverse events to ensure ongoing patient safety.

Canonical: https://hcco.app/knowledge/how_does_the_fda_approve_software_as_a_medical_device.php
Markdown: https://hcco.app/knowledge/how_does_the_fda_approve_software_as_a_medical_device.php/index.md
